

Supplementary Materials

Treatment with Targeted Therapy in Patients with Psoriatic Arthritis and Inadequate Response to Methotrexate: Proposal for a Rational Strategy

Philippe Goupille¹, Guillermo Carvajal Alegria¹, Frank Verhoeven², Daniel Wendling²

¹ Rheumatology Department, CHU de Tours; UPR CNRS 4301 CBM, NMNS, University of Tours, Tours. France

² Rheumatology Department, CHU de Besançon; University of Franche-Comté, Besançon, France

Correspondence: Philippe Goupille

Rheumatology Department, Trousseau Hospital, CHU de Tours, 37044 Tours cedex 9, France

Email: goupille@med.univ-tours.fr

Table S1. Keywords used in Pubmed literature search

6 Key Points	Search Terms
The tolerance of MTX	Methotrexate - Tolerance
The efficacy of targeted therapies combined with MTX vs monotherapy	Targeted therapies – PsA – Monotherapy – With methotrexate
Immunogenicity of anti-TNF α mAbs	Anti-TNF mAbs – Immunogenicity - PsA
Immunogenicity of anti-IL-17, anti-IL-12/23 and anti-IL-23 mAbs	anti-IL-17, anti-IL-12/23 and anti-IL-23 mAbs - Immunogenicity
The therapeutic maintenance of anti-TNF α mAbs when combined or not with MTX	Anti-TNF α mAbs – Therapeutic maintenance – with or without methotrexate
The therapeutic maintenance of anti-IL-17 vs anti-TNF α mAbs as first-line targeted therapy	Therapeutic maintenance - anti-IL-17 - anti- TNF α

Anti-TNF α : anti-tumor necrosis factor alpha; IL: interleukin; mAbs: monoclonal antibodies; MTX: methotrexate; PsA: psoriatic arthritis;